"Carcinoma, Islet Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A primary malignant neoplasm of the pancreatic ISLET CELLS. Usually it involves the non-INSULIN-producing cell types, the PANCREATIC ALPHA CELLS and the pancreatic delta cells (SOMATOSTATIN-SECRETING CELLS) in GLUCAGONOMA and SOMATOSTATINOMA, respectively.
| Descriptor ID |
D018273
|
| MeSH Number(s) |
C04.557.470.200.025.290 C04.588.274.761.500 C04.588.322.475.500 C06.301.761.500 C06.689.667.500 C19.344.421.500
|
| Concept/Terms |
Carcinoma, Islet Cell- Carcinoma, Islet Cell
- Carcinomas, Islet Cell
- Islet Cell Carcinoma
- Islet Cell Carcinomas
- Islet Cell Tumor, Malignant
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Islet Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Islet Cell".
This graph shows the total number of publications written about "Carcinoma, Islet Cell" by people in this website by year, and whether "Carcinoma, Islet Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 2 | 0 | 2 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Islet Cell" by people in Profiles.
-
Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes. J Surg Oncol. 2012 May; 105(6):595-600.
-
The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev. 2010 Aug; 31(4):578-99.
-
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008 Sep 10; 26(26):4311-8.
-
Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007 Dec; 14(12):3492-500.
-
Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab. 2007 Mar; 21(1):163-72.
-
Islet cell tumors. Curr Probl Surg. 2006 Oct; 43(10):685-765.
-
Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg. 2006 Jan; 10(1):138-45.
-
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005 Oct 15; 104(8):1590-602.
-
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004 Dec 01; 22(23):4762-71.
-
Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg. 2003 Sep; 238(3):423-31; discussion 431-2.